We examined whether different durations of exposure to relevant establishing operations (EO) during treatment of problem behavior affected treatment efficacy and response bursting. In Study 1, we compared 2 functional communication training (FCT) interventions. In the first treatment, we used a card touch as the target mand; this was associated with limited exposure to the EO because we could physically guide the mand at prescribed times. In the other treatment, we used a vocal response as the mand; this was associated with longer exposure to the EO because it was not possible to guide the response. In Study 2, we exposed participants to time-based reinforcement schedules that were yoked to the schedules of obtained reinforcement from the 2 FCT interventions in Study 1. Results indicated that limited exposure to the EO was associated with less response bursting, larger and more rapid reductions in problem behavior, and faster acquisition of the alternative mand.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452981 | PMC |
http://dx.doi.org/10.1002/jaba.180 | DOI Listing |
Alzheimers Dement
December 2024
Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Preclinical Alzheimer's disease (AD) trials can involve multiple years of follow-up and burdensome procedures for older individuals. Optimizing the design and conduct of these trials requires input from participants and their families. Since 2020, the Alzheimer's Clinical Trials Consortium (ACTC) Research Participant Advisory Board has provided input on study attributes including: participant and study partner compensation, consent language, and result communication tools.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Moravian University, PA, PA, USA.
Background: Given the widespread of tele-assessment and tele-rehabilitation in speech language pathology and clinical neuropsychology for monolingual English-speaking patients with acquired neurogenic language and cognitive disorders, there is an urgent need to implement a culturally and linguistically tailored telepractice for multilingual people living with dementia (MPLWD), for whom there is no consensus on a standard model. This study aims to investigate the delivery model of remote assessment and intervention for this population.
Method: A systematic scoping review was conducted in December 2023 following frameworks described by Arksey and O'Malley (2007).
Alzheimers Dement
December 2024
Chung-Ang University, Seoul, Seoul, Korea, Republic of (South).
Background: Long-term care hospitals are the main healthcare setting for the growing population with dementia in South Korea. Despite various deficiencies (e.g.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Acumen Pharmaceuticals, Charlottesville, VA, USA.
Background: Incorporation of the patient voice into drug development has been recognized as fundamental; recent legislation has addressed the importance of collecting patient experience data. Qualitative patient interviews conducted in tandem with clinical trials, often in later phases, are among the most common means of eliciting these data. To assess aspects of patient experience earlier in development, we conducted semi-structured qualitative interviews following participation in the phase 1 ACU-001 (INTERCEPT-AD) trial, a study evaluating the safety and tolerability of the Aβ oligomer-targeting monoclonal antibody ACU193, among a subset of participants with mild cognitive impairment (MCI) or mild Alzheimer's disease (AD) and their study partners.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!